Business
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes
Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection ...
About this update from Discovery Harbour Resources Corp.
[{"type":"text","content":"Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes\n\n\nBeckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nPR Newswire\n\n\nModeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing BREA, Calif., April 13, 2026 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.\n\n\n\n\n\n\n\nValidated for use across Beckman Coulter's installed base of DxI 9000 and Access 2 immunoassay analyzers, the Access MeMed BV assay enables fast, reliable infection differentiation while leveraging laboratories' existing infrastructure and workflows. Beckman Coulter partnered with MeMed, a leader in advanced host‑response technologies, to bring the proven MeMed BV® test into core laboratory settings. The MeMed BV test has been shown to enhance clinical decision‑making, support clinicians in curbing unnecessary antibiotic use, and advance antimicrobial‑stewardship initiatives—results reinforced by strong clinical studies and real‑world performance data.1-7Published MeMed economic data, together with incidence estimates for lower respiratory tract infections (LRTI) and community‑acquired pneumonia (CAP), indicate that European healthcare systems shoulder significant avoidable costs each year.8-10 With Access MeMed BV now available on Beckman Coulter's extensive installed base across Europe, healthcare systems have a scalable, practical path to help potentially reduc...